The role of the brain opioid system in alcohol dependence has been the subject of much research for over 25 years. This review explores the evidence: firstly describing the opioid receptors in terms of their individual subtypes, neuroanatomy, neurophysiology and ligands; secondly, summarising emerging data from specific neurochemical, behavioural and neuroimaging studies, explaining the characteristics of addiction with a focus on alcohol dependence and connecting the opioid system with alcohol dependence; and finally reviewing the known literature regarding opioid antagonists in clinical use for alcohol dependence. Further interrogation of how modulation of the opioid system, via use of MOP (mu), DOP (delta) and KOP (kappa) agents, restores the balance of a dysregulated system in alcohol dependence should increase our insight into this disease process and therefore guide better methods for understanding and treating alcohol dependence in the future.
AdinoffBKrebaumSRChandlerPA. (2005) Dissection of hypothalamic-pituitary-adrenal axis pathology in 1-month-abstinent alcohol-dependent men, part 2: Response to ovine corticotropin-releasing factor and naloxone. Alcohol Clin Exp Res29: 528–537.
2.
AltshulerHLPhillipsPEFeinhandlerDA (1980) Alteration of ethanol self-administration by naltrexone. Life Sci26: 679–688.
3.
AnokhinaIPIvanetsNNBurovYV. (1987) Alcohol and alcohol problems research 13: U.S.S.R. Br J Addict82: 23–30.
4.
AntonRFMoakDHWaidLR. (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiat156: 1758–1764.
5.
AntonRFMyrickHWrightTM. (2011) Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiat168: 709–717.
6.
AsaliLABrownKF (1984) Naloxone protein binding in adult and foetal plasma. Eur J Clin Pharmacol27: 459–463.
7.
BartGSchlugerJHBorgL. (2005) Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity. Neuropsychopharmacol30: 2254–2262.
8.
BazovIKononenkoOWatanabeH. (2013) The endogenous opioid system in human alcoholics: Molecular adaptations in brain areas involved in cognitive control of addiction. Addict Biol18:161–169.
9.
BenjaminDGrantERPohoreckyLA (1993) Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res621: 137–140.
10.
BerkowitzBA (1976) The relationship of pharmacokinetics to pharmacological activity: Morphine, methadone and naloxone. Clin Pharmacokinet1: 219–230.
11.
BierutLJ (2011) Genetic vulnerability and susceptibility to substance dependence. Neuron69: 618–627.
BlumKBriggsAHWallaceJE. (1987) Regional brain [met]-enkephalin in alcohol-preferring and non-alcohol-preferring inbred strains of mice. Experientia43: 408–410.
14.
BoettigerCAKelleyEAMitchellJM. (2009) Now or later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. Pharmacol Biochem Behav93: 291–299.
15.
BruijnzeelAW (2009) Kappa-opioid receptor signalling and brain reward function. Brain Res Rev62: 127–146.
16.
ChangGBarsonJRKaratayevO. (2010) Effect of chronic ethanol on enkephalin in the hypothalamus and extra-hypothalamic areas. Alcohol Clin Exp Res34: 761–770.
17.
ChesseletMFCheramyAReisineTD. (1983) Local and distal effects induced by unilateral striatal application of opioids in the absence or in the presence of naloxone on the release of dopamine in both caudate nuclei and the substantiae nigrae of the cat. Brain Res258: 229–242.
18.
ChickJAntonRChecinskiK. (2000) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol35: 587–593.
19.
CiccocioppoRMartin-FardonRWeissF (2002) Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacol27: 391–399.
20.
CloningerCR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science236: 410–416.
21.
ColasantiASearleGELongCJ. (2012) Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol Psychiatry72: 371–377.
22.
ContetCKiefferBLBefortK (2004) Mu opioid receptor: A gateway to drug addiction. Curr Opin Neurobiol14: 370–378.
23.
CowanAZhuXZMosbergHI. (1988) Direct dependence studies in rats with agents selective for different types of opioid receptor. J Pharm Exp Therap246: 950–955.
24.
CroopRSFaulknerEBLabriolaDF (1997) The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psych54: 1130–1135.
25.
D’AddarioCCaputiFFRimondiniR. (2013) Different alcohol exposures induce selective alterations on the expression of dynorphin and nociceptin systems related genes in rat brain. Addict Biol18: 425–433.
26.
DaglishMRWeinsteinAMaliziaAL. (2003) Functional connectivity analysis of the neural circuits of opiate craving: ‘More’ rather than ‘different’?Neuroimage20: 1964–1970.
27.
DavidsonDPalfaiTBirdC. (1999) Effects of naltrexone on alcohol self-adminstration in heavy drinkers. Alcohol Clin Exp Res23: 195–203.
28.
DavidsonDSwiftRFitzE (1996) Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res20: 732–739.
29.
De BrabanderBDeclerckCH (2004) A possible role of central dopamine metabolism associated with individual differences in locus of control. Pers Individ Dif37: 735–750.
30.
De WaeleJGianoulakisC (1993) Effects of single and repeated exposures to ethanol on hypothalamic β-endorphin and CRH release by the C57BL/6 and DBA/2 strains of mice. Neuroendocrinology57: 700–709.
31.
DevineDPLeonePPocockD. (1993) Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: In vivo microdialysis studies. J Pharmacol Exp Ther266: 1236–1246.
32.
DevinePWiseR (1994) Self-administration ventral tegmental of morphine, DAMGO, and DPDPE into the area of rats. J Neurosci14: 1978–1984.
33.
Di ChiaraGImperatoA (1988a) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci85: 5274–5278.
34.
Di ChiaraGImperatoA (1998b) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther244: 1067–1080.
35.
Di ChiaraGNorthR (1992) Neurobiology of opiate abuse. Trends Pharm Sci13: 185–193.
36.
DixonRGentileJHsuHB. (1987) Nalmefene: Safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol27: 233–239.
37.
DixonRHowesJGentileJ. (1986) Nalmefene: Intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther39: 49–53.
38.
DrobesDJAntonRFThomasSE. (2003) A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: Naltrexone and nalmefene. Neuropsychopharmacol28: 755–764.
39.
DrobesDJAntonRFThomasSE. (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res28: 1362–1370.
40.
DucciFGoldmanD (2008) Genetic approaches to addiction: Genes and alcohol. Addiction103: 1414–1428
41.
DumontMLemaireS (1985)Interaction of dynorphin with kappa opioid receptors in bovine adrenal medulla. Neuropeptide6: 321–329.
42.
DymshitzJLieblichI (1987) Opiate reinforcement and naloxone aversion, as revealed by place preference paradigm, in two strains of rats. Psychopharmacology(Berl)92: 473–477.
43.
EmmersonPJLiuMRWoodsJH. (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther271: 1630–1637.
44.
FemeníaTManzanaresJ (2012) Increased ethanol intake in prodynorphin knockout mice is associated to changes in opioid receptor function and dopamine transmission. Addict Biol17: 322–337
45.
FloryJDPytteCLHurdY. (2011) Alcohol dependence, disinhibited behavior and variation in the prodynorphin gene. Biol Psychol88: 51–56
46.
FryeRFMatzkeGRSchadeR. (1997) Effects of liver disease on the disposition of the opioid antagonist nalmefene. Clin Pharmacol Ther61: 15–23.
47.
FudalaPJHeishmanSJHenningfieldJE. (1991) Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther49: 300–306.
48.
GalTJDiFazioCADixonR (1986) Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther40: 537–542.
49.
GianoulakisC (1990) Characterization of the effects of acute ethanol administration on the release of beta-endorphin peptides by the rat hypothalamus. Eur J Pharmacol180: 21–29.
GianoulakisCBarcombA (1987) Effect of acute ethanol in vivo and in vitro on the β-endorphin system in the rat. Life Sci40: 19–28.
52.
GonzalesRJaworskiJ (1997) Alcohol and glutamate. Alcohol Health Res World21: 120–127.
53.
GonzalesRWeissF (1998) Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci18: 10663–10671.
54.
GouarderesCCrosJQuirionR (1985) Autoradiographic localization of mu, delta and kappa opioid receptor binding sites in rat and guinea pig spinal cord. Neuropeptides6: 331–342.
55.
GualAHeYTorupL.; for the ESENSE 2 Study Group (2013) A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. Epub ahead of print. DOI: doi:pii: S0924-977X(13000758.10.1016/j.euroneuro.2013.02.006
56.
HaywardMDSchnaich-BorgAPintarJE (2006) Differential involvement of endogenous opioids in sucrose consumption and food reinforcement. Pharmacol Biochem Behav85: 601–611.
57.
HeiligMKoobG (2007) A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci30: 399–406.
58.
HeimerLSwitzerRDvan HoesenGW (1982) Ventral striatum and ventral pallidum: Components of the motor system. Trends Neurosci5: 83–87.
59.
HeinalaPAlhoHKiianmaaK. (2001)Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol21: 287–292.
60.
HeinzALoberSGeorgiA. (2003) Reward craving and withdrawal relief craving: Assessment of different motivational pathways to alcohol intake. Alcohol Alcohol38: 35–39.
61.
HeinzAReimoldMWraseJ. (2005) Correlation of stable elevations in striatal µ-opioid receptor availability in detoxified alcoholic patients with alcohol craving. Arch Gen Psychiat62: 57–64.
62.
HenriksenGWillochF (2008) Imaging of opioid receptors in the central nervous system. Brain131: 1171–1196.
63.
HerzA (1997) Endogenous opioid systems and alcohol addiction. Psychopharmacology(Berl)129: 99–111.
64.
HoutaniTNishiMTakeshimaH. (2000) Distribution of nociceptin/orphanin FQ precursor protein and receptor in brain and spinal cord: A study using in situ hybridization and X-gal histochemistry in receptor-deficient mice. J Comp Neurol424: 489–508.
65.
HugeVRammesGBeyerA. (2009) Activation of kappa opioid receptors decreases synaptic transmission and inhibits long-term potentiation in the basolateral amygdala of the mouse. Eur J Pain13: 124–129.
66.
HyytiaP (1993) Involvement of mu-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol Biochem Behav45: 697–701.
67.
HyytiaPSinclairJD (1993) Responding for oral ethanol after naloxone treatment by alcohol-preferring AA rats. Alcohol Clin Exp Res17: 631–636.
68.
IngmanKHagelbergNAaltoS. (2005) Prolonged central µ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacol30: 2245–2253.
69.
IovchevaMZlatevaSAsparuhovaMS (2007) Precipitated withdrawal reaction to opiates in cases of improper use of naltrexone. Addict Biol1: 75–77.
70.
JohnsonNHoughtenRPasternakGW (1982) Binding of [3H]-β-endorphin in rat brain. Life Sci31: 1381–1384.
71.
JuneHLCummingsREilerWJA. (2004) Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviours in alcohol-preferring (P) rats. Neuropsychopharmacol29: 285–299.
72.
JuneHLGreyCWarren-ReeseC. (1998) The opioid receptor antagonist nalmefene reduces responding behaviour maintained by ethanol presentation: Preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res22: 2174–2185.
73.
JuneHLMcCaneSRZinkRW. (1999) The δ2-opioid receptor antagonist naltriben reduces motivated responding for ethanol. Psychopharmacology (Berl)147: 81–89.
74.
KakidaniHFurutaniYTakahashiH. (1982) Cloning and sequence analysis of cDNA for porcine B-neo-endorphin/dynorphin precursor. Nature298: 245–249.
75.
KarahanianEQuintanillaMETampierL. (2011) Ethanol as a prodrug: Brain metabolism of ethanol mediates its reinforcing effects. Alcohol Clin Exp Res35: 606–612.
76.
KendlerKSJacobsonKCPrescottCA. (2003) Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry160: 687–695
77.
KimSWagnerHNVillemagneVL. (1997) Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med38: 1726–1731.
78.
KingACVolpicelliJRFrazerA. (1997) Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl)129: 15–22.
79.
KitchenISloweSJMatthesHWD. (1997) Quantitative autoradiographic mapping of µ-,δ- and κ-opioid receptors in knockout mice lacking the u-opioid receptor gene. Brain Res778: 73–88.
80.
KleinGJuniAAroutC. (2008) Acute and chronic heroin dependence in mice: Contribution of opioid and excitatory amino acid receptors. Eur J Pharmacol586: 179–188.
81.
KoobGF (2000) Animal models in craving research: Animal models of craving for alcohol. Addiction95: S73–S81.
82.
KovacsKMSzakallIO’BrienD. (2005) Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol Clin Exp Res29: 730–738.
83.
KranzlerHRModesto-loweVKirkJ (2000) Naltrexone vs nefazodone for treatment of alcohol dependence. Neuropsychopharmacol22: 493–503.
84.
KranzlerHRModesto-LoweVNuwayserES (1998) Sustained-release naltrexone for alcoholism treatment: A preliminary study. Alcohol Clin Exp Res22: 1074–1079.
85.
KreekMJSchlugerJBorgL. (1999) Dynorphin A1–13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: Gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther288: 260–269.
86.
Krishnan-SarinSJingSLKurtzDL. (1995a) The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology (Berl)120: 177–185.
87.
Krishnan-SarinSPortoghesePSLiT. (1995b) The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol Biochem Behav52: 153–159.
88.
Krishnan-SarinSWandGSLiXW. (1998) Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. Pharmacol Biochem Behav59: 627–635.
89.
LamMPMarinelliPWBaiL. (2008) Effects of acute ethanol on opioid peptide release in the central amygdala: An in vivo microdialysis study. Psychopharmacology (Berl)201: 261–271.
90.
LaphamSFormanRAlexanderM. (2008) The effects of extended-release naltrexone on holiday drinking in alcohol dependent patients. J Subst Abuse Treat36: 1–6.
91.
LawPLohHHLiCH (1979) Properties and localization of B-endorphin receptor in rat brain. Proc Natl Acad Sci76: 5455–5459.
92.
Le MerrerJBeckerJAJBefortK. (2009) Reward processing by the opioid system in the brain. Physiol Rev89: 1379–1412.
93.
LeeMCWagnerHNTanadaS. (1988) Duration of occupancy of opiate receptors by naltrexone. J Nucl Med29: 1207–1211.
94.
LinsemanMLeAD (1997) Effects of opioids on the absorption of alcohol. Pharmacol Biochem Behav58: 79–84.
95.
LittletonJ (2000) Animal models in craving research: Can craving be modelled in animals? The relapse prevention perspective. Addiction95: S83–S90.
MangoldDMcCaulMEAliM. (2000) Plasma adrenocorticotropin responses to opioid blockade with naloxone: Generating a dose-response curve in a single session. Biol Psychiatry48: 310–314.
98.
MannKBladströmATorupL. (2013) Extending the treatment options in alcohol dependence: A randomized controlled study of as-needed nalmefene. Biol Psychiatry2013; 73: 706–713.
99.
MannKKieferFSpanagelR. (2008) Acamprosate: Recent findings and future research directions. Alcohol Clin Exp Res32: 1105–1110
100.
MansourAFoxCAAkilH. (1995) Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci18: 22–29.
101.
MansourAKhachaturianHLewisME. (1987) Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci7: 2445–2464.
102.
Marfaing-JallatPMiceliDLe MagnenJ (1983) Decrease in ethanol consumption by naloxone in naive and dependent rats. Pharmacol Biochem Behav18: S537–S539.
MarinelliPWLamMBaiL. (2006) A microdialysis profile of dynorphin A(1–8) release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res30: 982–990.
105.
MarkTLKassedCAVandivort-WarrenR. (2009) Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug Alcohol Depend99: 345–349.
106.
MartinWREadesCGThompsonJA. (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharm Exp Ther197: 517–532.
107.
MartinWRJasinskiDRManskyPA (1973) Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psych28: 784–791.
108.
MasonBJRitvoECMorganRO. (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res18: 1162–1167.
109.
MasonBJSalvatoFRWilliamsLD. (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psych56: 719–724.
110.
MengFXieGThompsonRC. (1993) Cloning and pharmacological characterization of a rat κ opioid receptor. Proc Natl Acad Sci90: 9954–9958.
111.
MeunierJMollereauCTollL. (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature377: 532–535.
112.
MeyerMCStraughnABLoM. (1984) Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry45: 15–19.
113.
MichaelisEFMichaelisMLFreedWJ. (1993) Glutamate receptor changes in brain synaptic membranes during chronic alcohol intake. Alcohol Alcoholsuppl 2: S377–S381.
114.
MichelMEBolgerGWeissmanBA (1985). Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol7: 175–177.
115.
MihicS (1999) Acute effects of ethanol on GABA A and glycine receptor function. Neurochem Int35: 115–123.
116.
MitchellJMO’NeillJPJanabiM. (2012) Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci Transl Med4: 1–8.
117.
MitchellJMTavaresVCFieldsHL. (2007) Endogenous opioid blockage and impulsive response in alcoholics and healthy controls. Neuropsychopharmacology32: 439–449.
118.
MollereauCParmentierMMailleuxP. (1994) ORL1, a member of the opioid receptor family. FEBS Lett341: 33–38.
119.
MoosRHMoosBS (2006)Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction101: 212–222.
120.
MorganCJBadawyAAThomasR. (1989) The [lactate]/[pyruvate] ratio and alcohol metabolism: Experiments with naloxone in fasting normal male volunteers. Alcohol Alcohol24: 185–188.
121.
MuchaRHerzA (1985) Psychopharmacology Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacol86(3): 274–280.
122.
MyersRDMcMillenBAAdellA (1995) Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism: Epitome of cerebral complexity. Neurochem Int26: 337–342.
123.
NakanishiSInoueAKitaT. (1979) Nucleotide sequence of cloned cDNA for bovine corticotrophin-B-lipotrophin precursor. Nature278: 423–427.
National Institute for Health and Clinical Excellence (2011) CG115. Alcohol use disorders: Diagnosis, assessment and management of harmful drinking and alcohol dependence. Available at: http://www.nice.org.uk/guidance/CG115 (accessed 18 October 2011).
NealCRMansourAReinscheidR. (1999) Localisation of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurobiol406: 503–547.
129.
NestlerEJ (2000) Genes and addiction. Nat Genet26: 277–281.
130.
NodaMFurutaniYTakahashiH. (1982) Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature295: 202–206.
131.
O’LearyGBorrowJWeissRD (2001) Opioid antagonists in the treatment of alcohol dependence. Curr Psychiat Rep3: 484–488.
132.
O’MalleySJaffeAJChangG. (2002) Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psych49: 881–887.
133.
O’MalleySSJaffeAJChangG. (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry49: 881–887.
134.
OberlinBGBristowREHeightonME. (2010) Pharmacologic dissociation between impulsivity and alcohol drinking in high alcohol preferring mice. Alcohol Clin Exp Res34: 1363–1375.
135.
OliveMFKoenigHNNanniniMA. (2001) Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J Neurosci21: 1–5.
136.
OlmsteadMCOuagazzalAMKiefferBL (2009) Mu and delta opioid receptors oppositely regulate motor impulsivity in the signaled nose poke task. PLoS One4: e4410.
137.
OsbornMDLoweryJJSkorputAGJ. (2010) Life Sci86: 624–630.
138.
OswaldLMWandGS (2004) Opioids and alcoholism. Physiol Behav81: 339–358.
139.
OverstreetDHKampov-PolevoyABRezvaniAH. (1999) Suppression of alcohol intake by chronic naloxone treatment in P rats: Tolerance development and elevation of opiate receptor binding. Alcohol Clin Exp Res23: 1761–1771.
140.
PanZZ (1998) µ-Opposing actions of the κ-opioid receptor. Trends Pharmacol Sci19: 94–98.
141.
PeckysDLandwehrmeyerG (1999) Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: A 33P in situ hybridization study. Neurosci88: 1093–1135.
142.
PetersenEN (1992) The pharmacology and toxicology of disulfiram and its metabolites. Acta PsychScand Suppl369: 7–13.
143.
PhillipsTJWengerCDDorowJD (1997) Naltrexone effects on ethanol drinking acquisition and on established ethanol consumption in C57BL/6J mice. Alcohol Clin Exp Res21: 691–702.
144.
PrescottCAKendlerKS (1999) Age at first drink and risk for alcoholism: a noncausal association. Alcohol Clin Exp Res23:101–107.
145.
PrzewlockaBLasofiWPrzewtockiR (1992) Repeated ethanol administration decreases prodynorphin biosynthesis in the rat hippocampus. Neurosci Lett134: 195–198.
RayLAChinPFMiottoK (2010) Naltrexone for the treatment of alcoholism: Clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disorders – Drug Targets9: 13–22.
148.
ReidLDDelconteJDNicholsML. (1991) Tests of opioid deficiency hypotheses of alcoholism. Alcohol8: 247–257.
149.
RemmersAEClarkMJMansourA. (1999) Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. J Pharmacol Exp Ther288: 827–833.
150.
RobbinsTWEverittBJ (1992) Functions of dopamine in the dorsal and ventral striatum. Sem Neurosci4: 119–127.
RobertsAJMcDonaldJSHeyserCJ. (2000) mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther293: 1002–1008.
153.
RobinsonTEBerridgeKC (1993) The neural basis of drug-craving: An incentive-sensitization theory of addiction. Brain Res Rev18: 247–291.
154.
Rodríguez-AriasMAguilarMAManzanedoC. (2010) Preclinical evidence of new opioid modulators for the treatment of addiction. Exp Opin Invest Drugs19: 977–994.
155.
RohsenowDJColbySMMontiPM. (2000) Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res24: 1542–1549.
156.
RuttenKDe VryJBruckmannW. (2010) Effects of the NOP receptor agonist Ro65–6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats. Eur J Pharmacol645: 119–126.
157.
RuttenKDe VryJBruckmannW. (2011) Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats. Drug Alcohol Depend114: 253–256.
158.
SamsonHDoyleT (1985) Oral ethanol self-administration in the rat: Effect of naloxone. Pharmacol Biochem Behav22: 91–99.
159.
Sanchis-SeguraCCorreaMMiquelM. (2005) Catalase inhibition in the arcuate nucleus blocks ethanol effects on the locomotor activity of rats. Neurosci Lett376: 66–70.
160.
SeizingerBRBovermannKMaysingerD. (1983) Differential effects of acute and chronic ethanol treatment on particular opioid peptide systems in discrete regions of rat brain and pituitary. Pharmacol Biochem Behav18: 361–369.
161.
SharpeASamsonH (2001) Effect of naloxone on appetitive and consummatory phases of ethanol self-administration. Alcohol Clin Exp Res25: 1006–1011.
162.
ShippenbergTS (2009) The dynorphin/kappa opioid receptor system: A new target for the treatment of addiction and affective disorders?Neuropharmacol34: 247.
163.
ShippenbergTBals-KubikRHuberA. (1991) Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists. Psychopharmacology (Berl)103: 209–214.
164.
ShippenbergTSHerzASpanagelR. (1992) Conditioning of opioid reinforcement: Neuroanatomical and neurochemical substrates. Annals NY Acad Sci654: 347–356.
165.
ShippenbergTSZapataACheferVI (2007) Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther116: 306–321
166.
SimoninFGaveriaux-RuffCBefortK. (1995) κ-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci92: 7006–7010.
167.
SpanagelRHerzAShippenbergTS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci89: 2046–2050.
168.
StarostaANLeemanRFVolpicelliJR (2006) The BRENDA model: Integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract12: 80–89.
169.
SteinerHGerfenCR (1998) Role of dynorphin and enkephalin in the regulation of striatal output pathways and behaviour. Exp Brain Res123: 60–76.
170.
SwiftRMWhelihanWKuznetsovO. (1994) Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiat151: 1463–1467.
171.
TakemoriAEPortoghesePS (1984) Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists. Eur J Pharmacol104: 101–104.
172.
TaqiMMBazovIWatanabeH. (2011) Prodynorphin CpG-SNPs associated with alcohol dependence: Elevated methylation in the brain of human alcoholics. Addict Biol16: 499–509
173.
TiffanySTConklinCA (2000) Human models in craving research: A cognitive processing model of alcohol craving and compulsive alcohol use. Addiction95: S145-S153.
Ubeda-BanonINovejarqueAMohedano-MorianoA. (2007) Projections from the posterolateral olfactory amygdala to the ventral striatum: Neural basis for reinforcing properties of chemical stimuli. BMC Neurosci8: 103–112.
176.
UNDCP and WHO (1992) Report, Informal Expert Committee on the Craving Mechanism. Report no. V. 92-54439T.
177.
UrEWrightDMBoulouxPMG. (1997) The effects of spiradoline (U-62066E), a k-opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol120: 781–784.
178.
Van ReeJMSmythDGColpaertFC (1979) Dependence creating properties of lipotrophin c-fragment (β-endorphin): Evidence for its internal control of behaviour. Life Sci24: 495–502.
179.
VerebeyKMuleSJ (1975) Naltrexone pharmacology, pharmacokinetics, and metabolism: Current status. Amer J Drug Alcohol Abuse2: 357–363.
180.
VerheulRvan den BrinkWGeerlingsP (1999) A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol34: 197–222.
181.
VolpicelliJRAltermanAIHayashidaM. (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psych49: 876–880.
182.
VolpicelliJRRhinesKCRhinesJS. (1997) Naltrexone and alcohol dependence. Arch Gen Psych54: 737–742.
183.
WalkerBMKisslerJL (2013) Dissociable Effects of Kappa-Opioid Receptor Activation on Impulsive Phenotypes in Wistar Rats. Neuropsychopharmacology. Epub ahead of print. DOI: 10.1038/npp.2013.129.
184.
WalkerBMKoobGF (2008a) Pharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence. Neuropsychopharmacol33: 643–652.
185.
WalkerBMKoobGF (2008b) Regarding ‘Dynorphin is a downstream effector of striatal BDNF regulation of ethanol intake’FASEB J22: 2113–2114.
186.
WandGMccaulMEGotjenD. (2001) Alcohol-dependent individuals have greater hypothalamic-pituitary-adrenal axis activation induced by naloxone compared with offspring without a family history of alcohol dependence. Alcohol Clin Exp Res25: 1134–1139.
187.
WandGSMcCaulMYangX. (2002) The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacol26: 106–114.
188.
WandGSWeertsEMKuwabaraH. (2012) The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects. Addict Biol18: 181–192.
189.
WardRJLallemandFde WitteP (2009) Biochemical and neurotransmitter changes implicated in alcohol-induced brain damage in chronic or ‘binge drinking’ alcohol abuse. Alcohol Alcohol44: 128–135.
190.
WatsonBJTaylorLGReidAG. (2013) Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET. Addict Biol. Epub ahead of print. DOI:10.1111/adb.12073.
191.
WeeSKoobGF (2010) The role of the dynorphin-κ opioid system in reinforcing effects of drugs of abuse. Psychopharmacology (Berl)210: 121–135.
192.
WeertsEMKimYKWangGS. (2008) Differences in δ- and µ-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacol33: 653–665.
193.
WeertsEMWandGSKuwabaraH. (2011) Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. Alcohol Clin Exp Res35: 2162–2173.
194.
WeinshenkerDSchroederJ (2007) There and back again: A tale of norepinephrine and drug addiction. Neuropsychopharmacol32: 1433–1451.
195.
WilliamsTMDaglishMRCLingford-HughesA. (2007) Brain opioid receptor binding in early abstinence from opioid dependence. Br J Psychiatry191: 63–69.
196.
WilliamsTMDaviesSJTaylorLG. (2009) Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: An [11C]diprenorphine PET study. Eur Neuropsychopharmacol19: 740–748.
197.
World Health Organization (2000) International Guide for Monitoring Alcohol Consumption and Related Harm. Geneva: WHO.
198.
XiaoCYeJH (2008) Ethanol dually modulates GABAergic synaptic transmission onto dopaminergic neurons in ventral tegmental area: Role of mu-opioid receptors. Neurosci153: 240–248.
199.
XiaoCZhangJKrnjevićK. (2007) Effects of ethanol on midbrain neurons: Role of opioid receptors. Alcohol Clin Exp Res31: 1106–1113.
200.
XueiXDickDFlury-WetherillL. (2006) Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry11: 1016–1024
201.
Yancey-WronaJDallaireBBilskyE. (2011) 6B-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: An exploratory study. Pain Med12: 1727–1737.
202.
ZadinaJEHacklerLGeL. (1997) A potent and selective endogenous agonist for the μ-opiate receptor. Nature386: 499–502.
203.
ZhangSYuL (1995) Identification of dynorphins as endogenous ligands for an opioid receptor-like orphan receptor. J Biol Chem270: 22772–22776.
204.
ZhuJChenCXueJ. (1995) Cloning of a human κ-opioid receptor from the brain. Life Sci56: 201–207.
